Category
City Health News
2817 posts · page 271 of 282

City Health News
Rise in Respiratory Syncytial Virus infections among children in Kolkata, some requiring respiratory support.
Kolkata sees surge in RSV cases, straining pediatric care.

City Health News
Implementation of government standard treatment protocols in cardiology, pulmonology, and dermatology to reduce over-treatment.
Streamlining treatment protocols can curb unnecessary procedures.

City Health News
Gene deletion in Candida fungus found to reduce resistance and virulence, opening new treatment avenues for antifungal therapy.
New gene deletion research paves the way for antifungal therapies.

City Health News
Outbreak of brain-eating amoeba (Naegleria fowleri) in Kerala with several confirmed cases and deaths, raising concerns over water safety.
Kerala faces a deadly outbreak of brain-eating amoeba, raising alarms.

City Health News
Indian pharma sector expecting modest growth due to pricing and regulatory challenges in the US market.
Indian pharma faces hurdles in the US, impacting growth.

City Health News
India’s pharmaceutical sector expanding global capability centres and R&D to move up the value chain in drug development.
India's pharma sector is enhancing R&D to boost global impact.

City Health News
Early onset of diabetes in India linked to sedentary work culture and lifestyle factors.
Sedentary lifestyles in India are fueling early diabetes cases.

City Health News
Eli Lilly investing $5 billion in a new Virginia plant to expand domestic production of APIs and therapies amid tariff concerns.
Eli Lilly boosts U.S. manufacturing with $5 billion Virginia plant.

City Health News
Roche acquiring US biotech 89bio for $3.5 billion to strengthen its pipeline in obesity and liver disease drugs.
Roche boosts its pipeline with 89bio acquisition for $3.5B.

City Health News
Big pharma companies pausing nearly £2 billion in planned UK investments due to regulatory pressures and unfavorable pricing policies.
Big pharma halts £2 billion UK investments amid regulatory woes.
